Blebbistatin suppresses smooth muscle contraction by disrupting the structure and arrangement of smooth muscle myosin rather than by inhibiting myosin light chain phosphorylation.
Answers are grounded in this paper and cite their sources.
Blebbistatin disrupts myosin filaments in animal smooth muscle; leaves open therapeutic relevance pending human validation.
To explore the precise mechanisms of the inhibitory effects of blebbistatin, a potent inhibitor of myosin II, on smooth muscle contraction, we studied the blebbistatin effects on the mechanical properties and the structure of contractile filaments of skinned (cell membrane permeabilized) preparations from guinea pig taenia cecum. Blebbistatin at 10 microM or higher suppressed Ca(2+)-induced tension development at any given Ca(2+) concentration but had little effects on the Ca(2+)-induced myosin light chain phosphorylation. Blebbistatin also suppressed the 10 and 2.75 mM Mg(2+)-induced, "myosin light chain phosphorylation-independent" tension development at more than 10 microM. Furthermore, blebbistatin induced conformational change of smooth muscle myosin (SMM) and disrupted arrangement of SMM and thin filaments, resulting in inhibition of actin-SMM interaction irrespective of activation with Ca(2+). In addition, blebbistatin partially inhibited Mg(2+)-ATPase activity of native actomyosin from guinea pig taenia cecum at around 10 microM. These results suggested that blebbistatin suppressed skinned smooth muscle contraction through disruption of structure of SMM by the agent.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: